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In the recent years, the serotonin system has emerged as a key player in the induction of
L-DOPA-induced dyskinesia (LID) in animal models of Parkinson’s disease. In fact, serotonin
neurons possess the enzymaticmachinery able to convert exogenous L-DOPA to dopamine
(DA), andmediate its vesicular storage and release. However, serotonin neurons lack a feed-
back control mechanism able to regulate synaptic DA levels. While in a situation of partial
DA depletion spared DA terminals can buffer DA released from serotonin neurons, the pro-
gression of DA neuron degeneration impairs this protective mechanism, causing swings in
synaptic DA levels and pulsatile stimulation of post-synaptic DA receptors. In line with this
view, removal of serotonin neurons by selective toxin, or pharmacological silencing of their
activity, produced complete suppression of LID in animal models of Parkinson’s disease.
In this article, we will revise the experimental evidence pointing to the important role of
serotonin neurons in dyskinesia, and we will discuss the clinical implications.
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THE ROLE OF STRIATAL PRE-SYNAPTIC NEURONS IN THE
APPEARANCE OF LID
l-DOPA, the precursor of dopamine (DA), represents the most
effective drug for alleviating motor symptoms in Parkinson’s dis-
ease (PD) patients. Its efficacy is due to the ability to restore
synaptic DA levels, an effect thought to be mediated by the spared
dopaminergic neurons. Indeed, it is known that at the time of
diagnosis something between 50 and 70% of nigral DA neurons
have already degenerated; the remaining neurons, however, have
the ability to take up the exogenous l-DOPA, convert it to DA,
store DA into vesicles, and mediate its synaptic release (1, 2).
The presence of the DA D2 auto-receptor at the pre-synaptic
membrane, which activates a feedback control mechanism able
to fine-tune the neurotransmitter release, allows the maintenance
of physiological-like synaptic DA levels. Thus, preservation of this
mechanism of regulation of DA release in spared DA terminals
avoids excessive post-synaptic DA receptor stimulation following
chronic l-DOPA administration in PD patients. Unfortunately,
the so-called honeymoon period does not last forever; in fact, it
is estimated that about 40 and 90% of patients suffer for motor
fluctuations, known as l-DOPA-induced dyskinesia (LID), within
the first 5 and 10 years from diagnosis, respectively. Thus, sooner
or later, most of the patients experience a significant worsening of
the therapeutic effect of l-DOPA and of their quality of life.
The current view on the risk factors underlying the develop-
ment of dyskinesias suggests that the progression of the dopamin-
ergic degeneration, rather than the duration of l-DOPA treatment,
makes the therapeutic effect to deteriorate over-time (3). Accord-
ingly, it has been shown that delaying the initiation of the l-DOPA
administration (using direct DA receptor agonists for the first few
years), while postpones the onset of dyskinesia compared to l-
DOPA monotherapy, does not reduce the severity of dyskinesia
once l-DOPA is introduced (4).
Interestingly, in a positron emission tomography (PET) study,
it has been demonstrated that dyskinetic patients present higher
synaptic DA levels 1 h after administration of l-DOPA compared
to stable responders (5). Thus, dyskinesias appear to be associated
to the inability to maintain synaptic DA levels within certain limits,
which is likely caused by the progression of DA neuron degener-
ation and consequent reduced ability to mediate controlled DA
release. In fact, in parkinsonian animals, severe dyskinesias develop
only in subjects with extensive DA lesion, while partial lesioned
animals show either none, or only mild dyskinesias. Elegant sup-
port to this view was provided by Ulusoy and collaborators (6); in
this study, a significant DA deficiency was induced in rats by viral
vector delivery of short hairpin RNA for the tyrosine hydroxy-
lase (TH) enzyme. Interestingly, DA-depleted rats were completely
resistant to the induction of dyskinesias following administra-
tion of a high dose of l-DOPA (even after being primed with
apomorphine), opposite to control animals with similar striatal
DA depletion. These results can be explained by the fact that
striatal DA terminals were largely preserved after inhibition of
DA synthesis, providing a buffering system for the exogenous
administered l-DOPA. In this situation, synaptic levels of DA
can be maintained within a physiological range by the presence
of D2 auto-receptors and DA transporter (DAT) on striatal DA
terminals. The ability of the pre-synaptic DA compartment to
prevent excessive DA receptor stimulation, even in presence of
supersensitive striatal DA receptors, is also confirmed in rat trans-
plantation studies. In fact, l-DOPA-primed dyskinetic rats tend
to normalize their response to l-DOPA after receiving ventral
mesencephalic DA grafts into the lesioned striatum, which recon-
stitute the pre-synaptic buffering capacity. The reduction of LID
is achieved despite post-synaptic DA receptors remain supersen-
sitive, as shown by the abnormal dyskinetic response of these
animals to amphetamine administration (7, 8).
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As further support pointing to similar mechanisms underlying
the appearance of dyskinesia in patients and animal models, dys-
kinetic rats have been shown to present higher extracellular DA
levels compared to non-dyskinetic animals after administration of
l-DOPA, as measured in microdialysis experiments (9, 10), simi-
lar to what seen by de la Fuente-Fernandez et al. (5) in dyskinetic
patients, in the aforementioned PET-imaging study.
Due to the intermittent oral administration of l-DOPA, synap-
tic DA peaks are rapidly followed by minimal neurotransmitter
levels, resulting in continuous fluctuations of synaptic DA con-
centration; this determines a pulsatile stimulation of post-synaptic
striatal DA receptors which is considered to be the driving force
for the induction of post-synaptic alterations at the level of striatal
neurons (5, 11).
In agreement with the key detrimental role of synaptic DA
swings in the appearance of LID, systems of continuous deliv-
ery of dopaminergic drugs, such as the continuous intraduodenal
infusion of l-DOPA (known as DuoDopa), are less susceptible of
inducing dyskinesias (11, 12). In fact, this treatment strategy is
adopted in cases of advanced disease, where motor fluctuations
are no longer manageable by modifying the regimen of the oral
therapy.
THE SEROTONERGIC SYSTEM IN LID: PRE-CLINICAL
EVIDENCE
Although the efficacy of the treatment is partly compromised in
advanced stage of disease, as it is in animal models of complete
DA denervation, l-DOPA still produces clear motor effects, of
which dyskinesias represent an abnormal manifestation; this sug-
gests that other cellular compartments can substitute the lost DA
neurons in mediating l-DOPA conversion to DA, and neurotrans-
mitter release. In this context, the serotonergic system has emerged,
in recent years, as a key player (1). In fact, serotonin neurons share
with the DA ones, the same enzymatic machinery required to con-
vert l-DOPA to DA and mediate vesicular storage, the aromatic
amino acid decarboxylase, and monoamine vesicular transporter,
respectively. In agreement, early studies have demonstrated the
ability of serotonin neurons to store DA after exogenous admin-
istration of l-DOPA (13, 14). However, serotonin neurons lack a
feedback control mechanism able to fine-tune the synaptic lev-
els of DA. As consequence, l-DOPA-derived DA is released in
an uncontrolled manner, leading to excessive synaptic DA peaks,
and contributing to swings in synaptic DA levels following oral
administration of l-DOPA; this will eventually determine pulsatile
stimulation of striatal post-synaptic DA receptors, and changes in
signaling cascades at striatal neurons (5, 9, 15–18).
Serotonin neurons are supposed to be involved in the releasing
of DA also in early stages of disease; however, such contribution
may initially be beneficial due to the presence of the spared DA
terminals that can buffer serotonin neuron-derived DA and avoid
excessive DA receptor stimulation (1). In support of this view, it
has recently been shown that a 30% reduction of striatal l-DOPA-
derived DA release is induced upon removal of serotonin nerve
fibers in DA neuron-intact rats (19).
Hence, as the DA neuron degeneration progresses, serotonin
neurons are expected to contribute more and more to conversion
of exogenously administered l-DOPA to DA, eventually producing
excessive DA receptor activation. In line with this view, removal
of serotonin innervation by 5,7-dihydroxytryptamine (5,7-DHT)
administration reduced l-DOPA-derived extracellular DA levels
by about 80% in the striatum of complete DA-lesioned rats (20).
Most importantly, removal of forebrain serotonin innervation
leads to near-complete suppression of LID in l-DOPA-primed
parkinsonian rats (15).
The involvement of serotonin neurons in the appearance of
LID in animal models has also been demonstrated with a pharma-
cological approach. In fact, silencing of serotonin neurons can be
achieved by targeting the serotonin auto-receptors with selective
agonists. Accordingly, several studies have shown a reduction of
LID induced by selective 5-HT1 receptor agonists in pre-clinical
animal models of PD (15, 16, 21–24). Moreover, co-administration
of 5-HT1A and 5-HT1B receptor agonists (8-OHDPAT and CP-
94253, respectively) in parkinsonian rats has been demonstrated
to produce a synergistic effect on reduction of LID, with complete
suppression at doses of the drugs that were ineffective when given
individually (15). Most importantly, this result was achieved also in
dyskinetic MPTP-treated macaques (24). In line with this hypoth-
esis, reduction of extracellular DA levels was found to account for
the potent anti-dyskinetic effect of 5-HT1A and 5-HT1B receptor
agonists on LID in a following rat microdialysis study (9).
Interestingly, similar results were also obtained with mixed 5-
HT1A/1B receptor agonists, such as eltoprazine and anpirtoline
in both rats and macaques, albeit a partial worsening of the ther-
apeutic effect of l-DOPA was seen at effective doses (25, 26). In
further support of a pre-synaptic action of 5-HT1A/1B receptor
agonists, doses able to fully suppress LID were ineffective against
dyskinesia produced by the DA direct agonist apomorphine (26,
27). This is relevant as 5-HT1A and 5-HT1B receptors are also
located post-synaptically, and their activation has been shown to
reduce striatal glutamate and GABA release, respectively (28, 29),
which is known to produce anti-dyskinetic effects; indeed, higher
doses of these compounds have been demonstrated to also reduce
dyskinesia induced by apomorphine (23).
The involvement of the serotonin neurons in the appearance
of LID has also been demonstrated in a rat PET-imaging study;
in fact, Nahimi and co-workers have shown that administra-
tion of 8-OH-DPAT could reverse l-DOPA-induced decrease of
[(11) C]raclopride binding and increase of extracellular DA in
6-OHDA-lesioned rats (30).
The interaction between l-DOPA and serotonin neurons has
been shown in another recent study, where administration of the
serotonin immediate precursor 5-hydroxy-tryptophan (5-HTP)
has produced anti-dyskinetic effect in parkinsonian rats; this effect
has been demonstrated to be partly mediated by activation of
serotonin auto-receptors and partly by displacement of DA from
serotonergic vesicles produced by the exogenous 5-HTP-derived
serotonin (31).
Even more striking results were obtained using selective sero-
tonin reuptake inhibitors (SSRIs), such as citalopram or fluox-
etine (32, 33), which are known to exert their anti-depressant
effect by increasing synaptic serotonin levels. In these studies,
the authors observed complete suppression of LID at relatively
low doses of drugs, while a 5-HT1 receptor antagonist appeared
to counteract this effect, suggesting that increased activation of
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serotonin auto-receptors is involved in the mechanisms of the
anti-dyskinetic effect of SSRIs in parkinsonian rats.
It should be noted that SSRIs and 5-HTP were found to produce
clear anti-dyskinetic effect without compromising the therapeutic
efficacy of l-DOPA in specific motor tasks. This is highly relevant
as it may suggest that worsening of the efficacy of l-DOPA seen
with selective 5-HT1 receptor agonists in parkinsonian rats may be
due to a transient reduction of the serotonergic tone. In fact, selec-
tive 5-HT1 receptor agonists are expected to reduce both DA and
serotonin release from serotonin neurons; by contrast, 5-HTP and
SSRIs are likely to reduce DA release without dampening synap-
tic serotonin levels. This is mostly important when thinking that
many advanced PD patients also suffer for symptoms of depres-
sion, and administration of selective 5-HT1 receptor agonists may
exacerbate this complication.
It should be noted that dampening of serotonin neuron release
by 5-HT1 receptor agonists did not only reduce LID, but it has also
been shown to prevent induction of post-synaptic alterations at
striatal neurons, such as increased expression of FosB and altered
synaptic NMDA receptor subunits distribution (24). This con-
firms that false transmitter release of DA from serotonin neurons
plays a key role in driving the maladaptive alterations that associate
with dyskinesia.
THE SEROTONERGIC SYSTEM IN LID: CLINICAL EVIDENCE
Whereas an overwhelming body of evidence proves a major role of
the serotonergic system in the appearance of LID in animal model,
clinical evidence are still scarce.
A large clinical study was conducted in the past years to inves-
tigate the efficacy sarizotan, a partial 5-HT1A receptor agonist,
in dyskinetic patients. Despite the promising results obtained in
pre-clinical experiments, and in an open-label study, the double-
blind investigation was terminated for lack of efficacy (34, 35).
While disappointing, these results may be due to the fact that
sarizotan also exerts antagonistic activity at the level of the D2
receptor (36). Moreover, it should be noted that sarizotan acts only
on the 5-HT1A receptor, while experimental evidence demon-
strated that a potent synergistic effect on suppression of LID is
obtained by simultaneous targeting of the 5-HT1A and 5-HT1B
auto-receptors (24, 26). Indeed, the mixed 5-HT1A/1B receptor
agonist eltoprazine, which we recently proved to be highly potent
on suppression of LID in animal models, is currently under clin-
ical investigation in a small group of dyskinetic patients, with
encouraging preliminary results (see http://www.psychogenics.
com/press2012.html).
Although it does not provide direct evidence for the involve-
ment of the serotonin system in LID, the results of the PET-
imaging study performed by de la Fuente-Fernandez et al. (5),
support the concept that dyskinesia is associated to dysregualted
DA release; in fact, in this study, dyskinetic patient showed higher
synaptic DA levels 1 h after l-DOPA administration compared to
stable responders.
In the same line, a key study has recently been performed by
Politis and co-workers (37). First, these authors showed that PD
patients with LID had relative preservation of serotonergic termi-
nals compared to patients with stable response to l-DOPA, which
correlated with the severity of LID, in agreement with a previous
post-mortem investigation (38). Moreover, in patients with LID
the same l-DOPA dose induced significant higher striatal synaptic
DA levels than in non-dyskinetic patients, as already seen by de la
Fuente-Fernandez et al (5). Most importantly, the partial 5-HT1A
receptor agonist buspirone, administered orally 15 min before l-
DOPA, significantly reduced the l-DOPA-evoked rises in striatal
synaptic DA release and attenuated LID (37). Whereas a previous
report has shown a partial reduction of LID following buspirone
administration (39), the study of Politis and colleagues provides
the first direct evidence that such reduction is linked to decreased
synaptic DA levels.
Whereas these results are extremely encouraging, a major con-
cern that emerged from animal studies is the preservation of the
l-DOPA therapeutic effect following dampening of serotonin neu-
rons activity. Thus, larger clinical studies should be performed to
address whether the therapeutic window is sufficient to take full
advantage from this approach to counteract LID in parkinsonian
patients, or to identify the subset of patients that are more likely
to benefit from 5-HT1 receptor agonists.
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